Logo

Genome Express Signs Partners on Mutacancer Program

Oct 28, 2005

NEW YORK, Oct. 28 (GenomeWeb News) - Genome Express will collaborate with France's Centre Léon Bérard in Lyon and the Centre Jean Perrin in Clermont Ferrand on the Mutacancer research program, the company said today.

 

Under the agreement, the Léon Bérard and the Jean Perrin centers gains access to the French company's technology and will keep the discoveries from the project. Genome Express will own any advances in screening technology.

 

Mutacancer, a sequencing program for mutational analysis of 300 gene candidates in human cancers, identifies diagnostic and therapeutic targets. The cancer diagnostics and therapeutics program targets breast, colon, and lung cancers.

 

Research results will be accessible to others in the healthcare sector, the partners said. They will consider offering joint services to the pharmaceutical industry.

Breaking News
The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.